REVELATION BIOSCIENCES, INC. (REVB): Nasdaq/NYSE listing notice — Nasdaq grants Revelation continued listing subject to reverse split and $1 price by Feb 14, 2025

REVELATION BIOSCIENCES, INC.

Nasdaq Panel granted continued listing; must effect reverse stock split by Jan 31, 2025.
Must maintain $1.00 bid price for 10 consecutive trading days by Feb 14, 2025.
Regained compliance with Nasdaq equity requirement (Rule 5550(b)(1)).
Company raised $4M from warrant exercise in December 2024.
FDA accepted Gemini IND; Phase 1b study in chronic kidney disease expected H1 2025.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

REVELATION BIOSCIENCES, INC. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

January 3, 2025, Revelation Biosciences, Inc. (the “Company”) received a decision letter issued by the Nasdaq Hearings Panel granting the Company’s request to continue its listing on The Nasdaq Stock Market, subject to e

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

REVELATION BIOSCIENCES, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 3, 2025, Revelation Biosciences, Inc. (the “Company”) received a decision letter issued by the Nasdaq Hearings Panel granting the Company’s request to continue its listing on The Nasdaq Stock Market, subject to e

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

REVELATION BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-25-002828

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.